Introduction
============

The endocannabinoid system consists of the cannabinoid type 1 (CB1) and cannabinoid type 2 (CB2) receptors, their endogenous ligands anandamide and 2-arachidonoyl glycerol and the enzymes involved in their biosynthesis and metabolism ([@ref-7]). CB1 is involved in the regulation of food intake, energy balance and metabolism of glucose and lipids ([@ref-8]). In clinical studies, CB1 receptor blockage by the selective CB1 antagonist rimonabant (SR141716A) induced weight loss and improvement in serum lipid, glucose and insulin levels by targeting central and peripheral CB1 receptors ([@ref-39]). However, some patients experienced depression, and this was considered an unacceptable side effect for treating obesity/metabolic syndrome. Hence, the drug was withdrawn from clinical use but there is remaining interest in some of its many potential medical applications ([@ref-5]; [@ref-43]) including treatment of various malignancies. It is therefore of interest to investigate possible adverse effects on blood cells in patients treated with rimonabant.

The endocannabinoid system is regulating various aspects of lymphocyte proliferation, maturation and immune response ([@ref-21]; [@ref-28]; [@ref-30]; [@ref-31]; [@ref-35]). Targeting the endocannabinoid system may therefore be a possible new treatment option in various lymphoproliferative disorders. CB1 receptors are expressed on cells of the immune system, but generally at lower levels than CB2 ([@ref-3]; [@ref-11]). We and others have found that CB1 and CB2 are highly expressed on neoplastic lymphocytes in malignant lymphoma ([@ref-15]; [@ref-17]; [@ref-27]; [@ref-42]). Targeting of CB1 and CB2 with endogenous or synthetic agonists reduced cell proliferation *in vitro* and *in vivo* and induced programmed cell death selectively in tumor cells of mantle cell lymphoma ([@ref-9]; [@ref-14]; [@ref-15]; [@ref-40]). Similarly, CB2 agonists induced cell death in T cell lymphoblastic leukemia ([@ref-27]). Also the CB1 antagonist rimonabant impaired proliferation and induced cell death in *ex vivo* isolated mantle cell lymphoma cells, alone, or in combination with anandamide ([@ref-9]). Others have reported antiproliferative effects of rimonabant on *in vitro* activated PBMC but not on freshly isolated, non-activated PBMC ([@ref-12]; [@ref-25]). These results show that CB1 blockade may have immunomodulatory and antiproliferative effects on malignant lymphoma and on activated normal lymphocytes *in vitro* but seems to spare resting lymphocytes. Very little is published on the effects of rimonabant on human PBMC *in vivo*, and the aim of this study was to investigate how treatment with rimonabant affected blood leukocytes. We therefore collected blood cells from obese patients treated with rimonabant and analyzed blood leukocytes by flow cytometry before and during treatment. To investigate which genes were differentially expressed in PBMC during rimonabant treatment, we used oligonucleotide arrays to compare gene expression profiles in PBMC before and at 4 weeks of treatment. This pilot study shows that rimonabant treatment induces expression of genes involved in immune responses but have only marginal effects on leukocyte subset frequencies in blood.

Materials and Methods
=====================

Patients and study design
-------------------------

Rimonabant was prescribed to eight patients, admitted to the Overweight Study Unit at the Department of Medicine, Karolinska University Hospital. Rimonabant was administered according to the manufacturers guidelines. All patients had a BMI \>35 kg/m^2^, were treated on clinical indications (metabolic and mechanical disability) and without mental disturbances. They were not included in any other study. The clinical characteristics of these patients are presented in [Table 1](#table-1){ref-type="table"}. Blood samples were collected before treatment and at the first clinical control, when the patients had received rimonabant, 20 mg daily, for 4 weeks. All patients gave their informed consent and the study was performed in accordance with the Declaration of Helsinki and approved by the Regional Ethical Committee in Stockholm.
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###### Clinical parameters of included subjects and percentages of blood cells as analyzed by flow cytometry before and after 4 weeks of rimonabant treatment.

Total T cells were defined as CD3+, CD4+ T cells as CD3+CD4+, CD8+ T cells as CD3+CD8+ and B cells as CD19+. The CD3−CD4+ cell population consists of monocytes and dendritic cells. The CD3−, CD16+ and/or CD56+ contain NK cells and monocytes with CD16 expression. There was a significant increase in CD3−, CD16+ and/or CD56+ cells after treatment (*p* = 0.049, paired *t*-test), all other changes were non significant.
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  Patient   Age, sex   Weight change (kg)   Leukocyte subsets as analyzed by flow cytometry[^\*^](#table-1fn1){ref-type="fn"}                                                                                                                
  --------- ---------- -------------------- ----------------------------------------------------------------------------------- ---------- ---------- ---------- ---------- ---------- --------- --------- ------------ ---------- --------- ---------
  1         50, F      nd                   75                                                                                  73         61         59         14         13         15        12        7.2          8          9         14
  2         41, F      −6.3                 58                                                                                  61         37         34         21         26         32        25        7            6.6        8         12
  3         55, F      nd                   72                                                                                  72         54         53         19         20         16        12        5.7          8          11        15
  4         56, M      −3.1                 70                                                                                  72         48         51         21         20         15        17        5.9          4.6        14        10
  5         47, F      −2.8                 75                                                                                  73         51         49         23         24         11        12        4.9          8          13        15
  6         44, F      0.0                  69                                                                                  70         51         50         17         19         20        18        3.9          4.6        8         12
  7         69, F      −2.0                 81                                                                                  81         37         35         45         46         8         8         3.3          3.4        9         11
  8         58, M      −3.0                 85                                                                                  87         52         53         32         40         4         3         2.1          5.7        7         9
  Median    52.5       2.9                  73.5                                                                                72.5       51         50.5       21         22         15        12        5.3          6.15       9         12
  (range)   (41--69)   (0--6.3)             (58--85)                                                                            (61--87)   (37--61)   (34--59)   (14--45)   (13--46)   (4--32)   (3--25)   (2.1--7.2)   (3.4--8)   (8--14)   (9--15)

**Notes.**

Values are percentage of cells in mononuclear gate.
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###### Genes differentially expressed in PBMC after treatment with rimonabant (ratio \>1.5 between rimonabant treated and controls, *p*-value \<0.001, false discovery rate \<0.1).
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  Probe set ID   Gene symbol   Fold change   *p*-value   Gene name
  -------------- ------------- ------------- ----------- -------------------------------------------------------------
  7953892        KLRF1         2.50          0.00046     Killer cell lectin-like receptor subfamily F, member 1
  7983910        AQP9          2.25          0.00033     Aquaporin 9
  8031207        LILRA2        2.10          0.00059     Leukocyte immunoglobulin-like receptor, subfamily A
  8078008        LSM3          2.00          0.00068     LSM3 homolog
  7981290        WARS          1.99          0.00028     Tryptophanyl-tRNA synthetase
  8149330        CTSB          1.90          0.00089     Cathepsin B
  8127534        C6orf150      1.87          0.00035     
  7919243        CD160         1.79          0.00096     CD160 molecule
  8130732        BRP44L        1.74          0.00073     Brain protein 44-like
  8110318        PRELID1       1.72          0.00084     PRELI domain containing 1
  8003953        PSMB6         1.69          0.00013     Proteasome subunit, beta type, 6
  8015545        RAB5C         1.68          0.00085     RAB5C, member RAS oncogene family
  8133690        MDH2          1.68          0.00081     Malate dehydrogenase 2
  8178676        NEU1          1.67          0.00052     Sialidase 1
  7973110        RNASE2        1.65          0.00028     Ribonuclease, RNase A family, 2
  026541         FAM32A        1.65          0.00032     Family with sequence similarity 32, member A
  8004247        C17orf49      1.64          0.00062     
  8088820        RYBP          1.63          0.00076     RING1 and YY1 binding protein
  8058373        WDR12         1.62          0.00077     WD repeat domain 12
  8071119        BCL2L13       1.61          0.00092     BCL2-like 13 (apoptosis facilitator)
  8174103        GK            1.61          0.00086     Glycerol kinase
  8016099        EFTUD2        1.60          0.00079     Elongation factor Tu GTP binding domain containing 2
  7914563        YARS          1.60          0.00086     Tyrosyl-tRNA synthetase
  979085         PYGL          1.59          0.00092     Phosphorylase, glycogen
  8004237        RNASEK        1.59          0.00049     Ribonuclease, RNase K
  7947681        ARHGAP1       1.58          0.00025     Rho GTPase activating protein 1
  7959153        COX6A1        1.57          0.00096     Cytochrome c oxidase subunit VIa polypeptide 1
  8017437        FTSJ3         1.56          0.00055     FtsJ homolog 3
  8049180        EIF4E2        1.55          0.00096     Eukaryotic translation initiation factor 4E family member
  8146934        LY96          1.54          0.00075     Lymphocyte antigen 96
  7900922        ATP6V0B       1.54          0.00064     ATPase, H+ transporting
  8037913        NAPA          1.53          0.00037     N-ethylmaleimide-sensitive factor attachment protein, alpha
  8037037        ATP5SL        1.52          0.00031     ATP5S-like
  8016708        LRRC59        1.51          0.00019     Leucine rich repeat containing 59
  8163383        SUSD1         1.51          0.00062     Sushi domain containing 1
  7990151        PKM2          1.51          0.00093     Pyruvate kinase, muscle
  7978123        PSME2         1.51          0.00065     Proteasome activator subunit 2
  8075564        RFPL2         −1.51         0.00020     Ret finger protein-like 2
  7900878        ARTN          −1.51         0.00041     Artemin
  8141228        TMEM130       −1.51         0.00075     Transmembrane protein 130
  8037298        CD177         −1.58         4.0e−005    CD177 molecule
  8069142        KRTAP10-4     −1.59         0.00023     Keratin associated protein 10-4
  8070771        KRTAP10-1     −1.60         0.00054     Keratin associated protein 10-1
  8172713        LOC347549     −1.61         0.00061     Hypothetical LOC347549
  8075200        RHBDD3        −1.63         0.00067     Rhomboid domain containing 3
  8167575        GAGE12B       −1.66         0.00028     G antigen 12B
  8010901        DOC2B         −1.82         0.00072     Double C2-like domains, beta

Flow cytometry
--------------

The phenotypes of cells in the blood were analyzed by flow cytometry according to standard procedures at the Hematopathology Unit, Dept. of Pathology, Karolinska University Hospital, using 6 color flow cytometry to detect T, B, NK cells and CD3− CD4+ cells (monocytes and dendritic cells). Flow cytometry was performed on a CANTO 1 flow cytometer (BD, Becton-Dickinson, Europe).

For data acquisition and analysis, a CANTO 1 flow cytometer (BD, Becton Dickinson, Europe) was used with Cell Quest software (Becton Dickinson, Franklin Lakes, New Jersey, USA). All samples were analyzed by setting appropriate side and forward scatter gates to identify the mononuclear cell population, using CD45 and forward and side scatter for gate setting. Consistency of analysis parameters was ascertained by calibrating the flow cytometer with calibrating beads and FacsComp software, both from Becton Dickinson. The results are reported as percentage of gated cells positive for each antibody. The following fluorochrome conjugated antibodies, all from BD, were used: CD4 PE, CD3 PerCP-Cy5.5, CD19 PE-Cy7, CD8 APC and CD45 APC-H7. We also used BD Multitest 6-Color TBNK Reagent containing CD3 FITC clone SK7, CD16 PE clone B73, CD56 PE clone NCAM 16.2, CD45 PerCP-Cy5.5 clone 2D1, CD4 PE-Cy7 clone SK3, CD19 APC clone SJ25C1 and CD8 APC-Cy7, clone SK1. The gating strategy is shown in [Fig. S1](#supp-1){ref-type="supplementary-material"}.

RNA isolation and oligonucleotide array hybridization
-----------------------------------------------------

Blood mononuclear cells were isolated by Ficoll separation (Ficoll-Paque PLUS, GE Healthcare, Little Chalfont, UK). From the cell-pellet total RNA was prepared using Qiagen midi plus kit (Qiagen GmbH, Hilden Germany) as recommended by the manufacturer and was quality controlled on an Agilent Bioanalyzer (Agilent Technologies, Inc. Palo Alto, California, USA). Six pretreatment samples and seven samples obtained after rimonabant treatment passed the quality control. The cRNA synthesis for microarray experiments and the hybridizations were carried out using Affymetrix Human Gene 1.0 ST Array (Affymetrix, Inc., Santa Clara, California, USA) according to standard Affymetrix protocols at the core facility for Bioinformatics and Expression Analysis, Department of Biosciences and Nutrition, Karolinska Institutet.

Gene expression data analysis
-----------------------------

We used tools provided in the Partek Genomic Suite 6.5 software (Partek Inc., St. Louis, Missouri, USA). Normalization was done by Robust Multiarray Analysis (RMA) followed by 1-way Analysis Of Variance (ANOVA) comparing the patient group before and after treatment. Significantly changed genes and exons were selected with an unadjusted *p*-value of \<0.001, a False Discovery Rate (FDR) \<0.1 and a fold-change equal or greater than \>1.5 for up regulated genes and equal or less than \<−1.5 for down regulated genes. Gene functional annotations were performed by using the free software **DAVID** v6.7 (Database for **A**nnotation, **V**isualization and **I**ntegrated **D**iscovery) ([@ref-16]). The gene expression data are deposited at the GEO repository under the number [GSE68055](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68055).

Statistical analysis
--------------------

Leukocyte subsets (as measured by flow cytometry) in blood before and after rimonabant treatment were analyzed using a paired *t*-test.

Results
=======

Analysis of PBMC by flow cytometry before and during treatment with rimonabant
------------------------------------------------------------------------------

Blood levels of mononuclear cells on eight obese patients were analyzed by flow cytometry before and during treatment with rimonabant. There were no significant changes in the relative frequencies of total CD3+ T cells, CD4+ T cells, CD8+ T cells, B cells or CD3--CD4+ cells (monocytes and dendritic cells) in the patients during the treatment period ([Table 1](#table-1){ref-type="table"}, graphically presented in [Fig. 1](#fig-1){ref-type="fig"}) There was however a trend towards an increase in percentage of CD3−, CD16+/and or CD56+ cells (before treatment median 9% range 7--14%; after treatment median 12% range 9--15% *p* = 0.049) ([Table 1](#table-1){ref-type="table"} and [Fig. 1](#fig-1){ref-type="fig"}).

![Percentage of peripheral blood mononuclear cells (PBMC) before and during treatment with rimonabant.\
PBMC were analyzed by flow cytometry before start of therapy and 4 weeks later and results are given as percentage of mononuclear cells in blood. Each data point represents results from one patient. In cases with no change in the frequency of a certain cell type the data point would fall on the line. The only statistically significant change was for CD3−, CD16+ and/or CD56+ cells (*p* = 0.049). For the other subsets the *p*-values were as follows: CD3+ *p* = 0.47; CD3 + CD4 + *p* = 0.25; CD3 + CD8 + *p* = 0.11; CD19+ *p* = 0.13; CD3--CD4+ *p* = 0.11. The mononuclear gate was defined by CD45 in combination with side and forward scatter. Within this gate the frequencies of CD3+ T cells, CD19+ B cells, CD3−, CD56+ and/or CD16+ cells (NK cells and subpopulation of CD16+ monocytes) and CD3−, CD4+ cells (monocytes and dendritic cells) were analyzed.](peerj-03-1056-g001){#fig-1}

Whole-transcript gene expression analysis demonstrates significant changes in genes belonging to innate immune system pathways
------------------------------------------------------------------------------------------------------------------------------

Treatment with rimonabant might influence the expression of genes in patient leukocytes. To explore possible differences in gene expression profiles, whole-transcript expression analysis of PBMC before and during treatment was done, using Affymetrix Human Gene 1.0 ST Arrays. 47 probe sets were significantly differently expressed during treatment with a fold change of at least 1, 5, 37 probe sets showed increased expression and 10 decreased expression, respectively ([Table 2](#table-2){ref-type="table"}). Several of the genes with significantly increased expression after rimonabant treatment are known components of the innate immune system (as exemplified by KLRF1, LILRA2, CTSB, CD160, CD177, and LY96). KLRF1 (also named NKp80) encodes a lectin-type of receptor that is expressed on nearly all NK cells and stimulates their cytotoxicity and cytokine release ([@ref-22]). LILRA2 is the gene for an immune receptor that is expressed on monocytes, B cells, NK cells and dendritic cells and affects antigen presentation and innate immune responses ([@ref-24]). CTSB encodes cathepsin B, a protein that can be expressed in several immune cells including monocytes and that is involved in cell migration and immune modulation ([@ref-36]). CD160 is an essential NK cell receptor and is involved in regulation of cytokine production (reviewed in [@ref-23]). CD177 is a GPI linked cell surface molecule that regulates activation and migration of neutrophil granulocytes ([@ref-37]). LY96 (also named MD-2) is associating with toll-like receptor 4 and is involved in signaling by LPS ([@ref-26]). A few genes promoting increased apoptosis were also upregulated (BCL-like 13, an apoptosis facilitator ([@ref-18]; [@ref-20]), RING1- and YY1-binding protein, a regulator of MDM2 ([@ref-4])).

It has previously been shown that chronic marijuana users have increased expression of CB1 in peripheral blood mononuclear cells ([@ref-29]). We therefore specifically analyzed the expression of genes belonging to the endocannabinoid system in our patient cohort. Rimonabant treatment did neither affect the expression of CB1 (mean and standard deviation of CB1 expression values before and after treatment were 12.5 ± 3.24 and 10.79 ± 2.43, respectively, corresponding to a fold change of −1.1) nor of CB2 or the enzymes involved in the degradation and/or synthesis of endocannabinoids (fatty acid amide hydrolase, FAAH, and N-acyl phosphatidylethanolamine phospholipase D, NAPEPLD) either when analyzed by gene expression analysis or by RT-PCR (data not shown).

Discussion
==========

In this study we investigated the possible effects on PBMC of treatment with the CB1 antagonist rimonabant in patients taking the drug for obesity. We found that the distribution of leukocyte subsets remained rather constant, as analyzed by flow cytometry before treatment and after 4 weeks of treatment with rimonabant with the exception of CD3−, CD16+ and/or CD56+ cells that increased after treatment. This subset includes NK cells (CD3−, CD56+ and/or CD16+) and also subsets of monocytes (CD3--CD16+). There were no significant changes in expression levels of cannabinoid receptors or enzymes involved in synthesis and metabolism of endocannabinoids. However gene expression analysis suggested that genes involved in metabolism, cell death and the innate immune system were up regulated during treatment.

Rimonabant is the first selective CB1 antagonist registered for clinical use and was clinically developed for treatment of obesity and the metabolic syndrome. Beside the effect on food intake, anti-proliferative actions on normal and malignant cells have been reported. Cannabinoid receptors are often more highly expressed on malignant cells than on their normal counterparts and cancer cells are usually more sensitive to the action of cannabinoids than normal cells (reviewed in [@ref-10]; [@ref-35]; [@ref-41]). Rimonabant has been reported to induce growth inhibition or apoptosis on several malignancies including breast, thyroid and colon cancer ([@ref-1]; [@ref-6]; [@ref-32]; [@ref-33]). We have previously demonstrated that mantle cell lymphoma and other B cell lymphomas have higher expression of CB1 and CB2 than normal lymphocytes ([@ref-15]; [@ref-17]; [@ref-42]). Cannabinoid receptor agonists, at 1--10 µM levels, reduced proliferation and induced programmed cell death in mantle cell lymphoma *in vitro* and in a xenotransplant model ([@ref-9]; [@ref-14]; [@ref-15]; [@ref-34]; [@ref-40]). Interestingly, similar concentrations of rimonabant induced cell death in *ex vivo* isolated mantle cell lymphoma cells ([@ref-9]). While these studies suggest that targeting of CB1 may be of use in cancer therapy, concern may be raised since anti-proliferative effects have been reported in PBMC ([@ref-25]). In these studies, rimonabant inhibited mitogen induced cell proliferation *in vitro* via G1/S phase arrest without induction of cell death ([@ref-25]). In contrast, [@ref-12] reported that freshly isolated PBMC are highly resistant to the cytotoxic and cytostatic effects of rimonabant compared to leukemia-derived cell lines. It is possible that the different sensitivity to CB1 antagonism in freshly isolated, compared to mitogen activated, PBMC may reflect differences in expression levels of CB1. Resting leukocytes express very low levels of CB1 ([@ref-3]; [@ref-11]; [@ref-19]) while receptor levels may increase upon activation by mitogens, cytokines or exposure to CB1 agonists ([@ref-2]; [@ref-29]; [@ref-34]). We did not detect any significant differences in expression levels of CB1 or other components of the endocannabinoid system during rimonabant treatment for 4 weeks. Furthermore, our studies on *ex vivo* isolated PBMC from rimonabant treated patients demonstrated very minor changes in frequencies of T cells, B cells, CD3−, CD16+ and/or CD56+ cells or CD3--CD4+ cells or on total lymphocyte counts, in line with the results of [@ref-12].

Global gene expression analysis demonstrated significant changes in genes coding for components of the innate immune system. The study design does not make it possible to discriminate if the differences in gene expression can be ascribed to certain subsets of leukocytes or if it is a general process, seen in all PBMC. However, many of the genes that were more highly expressed after treatment with rimonabant are expressed in NK cells (such as KLRF1 and CD160) and monocytes, which imply that the treatment is associated with the activation of certain inflammatory and immunological functions of the innate immune system. Interestingly, rimonabant has been shown to directly activate human and mouse macrophages and thereby inhibit the development of the intracellular pathogen Brucella suis ([@ref-13]). Furthermore, studies on lipopolysaccharide activated human macrophages showed that CB1 receptor blockade by rimonabant suppressed production of inflammatory cytokines (IL-1*β*, IL-6, IL-8, TNF-*α*) and matrix metalloproteinase-9 ([@ref-38]).

Conclusions
===========

In conclusion our results show that rimonabant treatment induces expression of genes involved in immune responses but have only marginal effects on leukocyte subset frequencies in blood. This is in marked contrast to previous studies in which rimonabant induced cell death in malignant B lymphocytes that express high levels of CB1 ([@ref-9]). The relatively small effects on normal leukocytes suggest that CB1 targeting may be further investigated as a therapeutic approach in lymphoma treatment, enabling selective effects of tumor cells.
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###### Gating strategy for CD3−, CD4+cells

The gating strategy is shown in the dendrogram. First a mononuclear cell gate was set. Within this gate subpopulations of CD3+ T cells, CD19+ B cells and CD3−, CD4+ cells were identified by additional gating.

###### 

Click here for additional data file.
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